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not sufficiently removed during the dialysis session in 
a considerable number of patients. Actually, it has 
been observed that majority of hemodialysis patients 
suffer from hyperuricemia 1）. Although the incidence 
of gout in hemodialysis patients is not necessarily 
increased 2）, the incidence of gout has been reported 
to be associated with an increased risk of cardiovascu-
lar and all-cause mortality in hemodialysis patients 3）. 
As to the treatment of hyperuricemia in hemodialysis 
patients, the effectiveness of diet therapy is limited 
and uricosuric agents do not work in nature, there-
fore, a xanthine oxidase inhibitor（XOI）has to be used 
in most cases in order to reduce serum uric acid 
????????????
Adequate control of circulating substances such as 
potassium, phosphate and uric acid is one of the 
important concerns in the long-term management of 
hemodialysis patients, because these substances are 
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More than few patients on maintenance hemodialysis present with hyperuricemia, and the control of 
serum uric acid level is an important issue in the long-term management. In addition to allopurinol, febuxo-
stat can be used as a xanthine oxidase inhibitor in hemodialysis patients. In this study, the clinical effects 
of febuxostat were compared with allopurinol in chronic hemodialysis patients. Eligible hemodialysis 
patients taking allopurinol were randomly assigned to take 100 mg allopurinol（n＝26）or 20 mg febuxostat
（n＝23）for 12 weeks. Serum uric acid was markedly lowered in the febuxostat group（0-week 6.7 mg/dL, 
12-week 4.3 mg/dL, p＜0.001）as compared with the allopurinol group（0-week 6.0 mg/dL, 12-week 
5.8 mg/dL）and systolic blood pressure was lowered by 5 mmHg（p＝0.036）at 4-week in the febuxostat 
group while blood pressure was not significantly changed in the allopurinol group throughout the study 
period. In addition, the dose of erythropoiesis stimulating agent was reduced（0-week 22.2 µg/wk, 
12-week, 17.1 µg/wk, p＝0.012）and serum phosphate level was lowered（0-week 5.9 mg/dL, 12-week 
5.1 mg/dL, p＝0.027）in the febuxostat group but not in the allopurinol group. It is concluded that febuxo-
stat is more effective in lowering serum uric acid than allopurinol in hemodialysis patients. In addition, it is 
suggested that febuxostat has an advantage in the management of renal anemia and hyperphosphatemia 
as well as hyperuricemia.
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effectively. For many years, allopurinol had been the 
only XOI available in medical practice, however, the 
use of allopurinol is limited in renal failure patients 
because oxypurinol, the metabolite of allopurinol, is to 
be excreted in the kidney and the risk of severe der-
matological side effects such as Stevens-Johnson syn-
drome and toxic epidermal necrosis is increased 4,5）. 
Thereafter, XOIs such as febuxostat and topiroxostat, 
which are excreted through the liver as well as 
through the kidneys, have become available 6〜8）. These 
new XOIs can be used in patients with reduced renal 
function including hemodialysis patients, however, the 
characteristics of their clinical effects do not seem to 
be fully clarified in detail and the benefits and the dis-
advantages have to be carefully examined not only as 
to the hypouricemic effect but also other side effects 
beneficial or detrimental to the patients.
In the present study, we compared the therapeutic 
effects of allopurinol and febuxostat in chronic hemodi-
alysis patients complicated by hyperuricemia and 
evaluated the usefulness of febuxostat in the long-
term management of hemodialysis patients.
???????
This study enrolled a total of 50 end-stage renal 
disease patients undergoing stable maintenance hemo-
dialysis as an outpatient for more than six months 
and given allopurinol 100 mg once daily for hyperuri-
cemia for more than three months. After the evalua-
tion of basic characteristics and laboratory examina-
tion described below, they were randomly divided into 
two groups. In 26 patients, one dose of allopurinol 
100 mg daily in the morning was continued. In other 
24 patients, allopurinol was switched to one dose of 
febuxostat 20 mg daily in the morning. And the 
administration of allopurinol or febuxostat was contin-
ued for 12 weeks. Other medications such as antihy-
pertensive drugs, anti-platelet drugs, vitamin D, phos-
phate binders and potassium binders were not 
changed during this 12-week study period.
Physical and laboratory examinations were per-
formed at 0-, 4-, 8- and 12-week of the study. Blood 
pressure（BP）was measured before each dialysis ses-
sion in the patients at a supine position after resting 
more than 10 minutes and the average value during 
one week was used for evaluation at each time 
point 9,10）. Body weight gains between dialysis sessions 
were also averaged for one week. Peripheral blood 
samples from arterio-venous fistula for hematological 
tests and blood chemistry were obtained before start-
ing the dialysis session and chest roentgenogram was 
taken at 0-, 4-, 8- and 12-week.
The study protocol was in accordance with the rec-
ommendations of the World Medical Association for 
biomedical research involving human subjects（For-
taleza version, 2013）and was approved by the institu-
tional review board. Informed consent was obtained 
from all subjects after explaining the study objective 
and design.
Clinical data were expressed as means±standard 
deviations（SD）except for the dose of darbepoetin 
alfa as erythropoiesis stimulating agent（ESA）where 
standard errors（SE）were used in drawing the graph. 
Values between the two groups were compared by 
t-test, however, Wilcoxon test was applied for the 
data with skewed distribution and the categorical data 
were compared using chi-square test. The time-
course changes in variables during the study periods 
were analyzed using two-way ANOVA for repeated 
measures followed by Tukey’s method for post-hoc 
multiple comparisons. A p value less than 0.05 was 
considered to indicate statistical significance.
???????
Among the 50 patients who were in the study a 
72-year-old woman, undergoing dialysis from chronic 
glomerulonephritis, experienced eruptions in her body 
trunk two days after starting febuxostat and the 
administration of febuxostat was stopped. Remaining 
49 patients showed good adherence to the therapy 
and fulfilled the whole study periods. Table 1 shows 
the background characteristics of these 49 patients. 
Age, gender and duration of hemodialysis were not 
significantly different between the group continuing 
allopurinol and the group changed to febuxostat. Dia-
betic nephropathy and chronic glomerulonephritis 
were the frequent causes of renal failure in either 
group. Physical parameters such as BP, heart rate and 
body mass index did not significantly differ between 
the two groups. The complication frequencies of cere-
brovascular, cardiovascular and other organ diseases 
were also comparable in the two groups.
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Table 2 lists the medications given to the subjects 
concurrently with allopurinol or febuxostat. The 
majority of patients were taking antihypertensive 
drugs, 73.1％ in the allopurinol group and 78.3％ in 
the febuxostat group. Calcium channel blockers and 
angiotensin II receptor blockers were the frequently 
used class of antihypertensive agents. In addition, 
most patients were taking phosphate binders and 
nearly half of the patients were taking active vitamin 
D as is the case with chronic hemodialysis patients. 
Antiplatelet drugs were also given to a more than 
half of the patients for the prevention of arteriovenous 
???????　Baseline characteristics of the study subjects given allopurinol or febuxostat
Total
n＝49
Allopurinol
n＝26
Febuxostat
n＝23
P value
Gender, male/female 31/18 17/9 14/9 0.743
Age, year 66.6±12.9 66.5±14.9 66.8±10.1 0.923
Cause of renal failure
　Diabetic nephropathy
　Chronic glomerulonephritis
　Nephrosclerosis
23（47％）
20（41％）
 6（12％）
13（50％）
 9（35％）
 4（15％）
10（43％）
11（48％）
 2（9％）
0.648
0.347
0.475
Duration of hemodialysis, year 9.0±9.4 9.4±9.6 8.5±9.11 0.733
Body mass index, kg/m2 20.4±2.4 20.8±2.5 19.8±2.2 0.168
Systolic BP, mmHg 140.8±16.8 139.9±18.2 141.8±15.0 0.698
Diastolic BP, mmHg 74.4±10.0 75.0±10.9 73.8±8.7 0.675
Heart rate, bpm 73.4±8.5 73.9±9.0 72.8±8.0 0.686
Complications
　Cerebrovascular disease 11（22％） 7（27％） 4（17％） 0.424
　Coronary artery disease  5（10％） 3（12％） 2（9％） 0.742
　Valvular heart disease 4（8％） 1（4％） 3（13％） 0.240
　Peripheral artery disease  6（12％） 4（15％） 2（9％） 0.475
　Chronic liver disease  5（10％） 2（8％） 3（13％） 0.536
　Chronic lung disease 3（6％） 1（4％） 2（9％） 0.479
Data are the mean±SD. BP, blood pressure.
???????　Medications concurrently given with allopurinol or febuxostat in study subjects
Allopurinol, n＝26 Febuxostat, n＝23
Diuretic 15（58％） 8（35％）
Adrenergic inhibitor 5（19％） 4（17％）
Calcium channel blocker 11（42％） 12（52％）
Renin-angiotensin system inhibitor 12（46％） 10（43％）
Antianginal drug 3（12％） 5（22％）
Antiplatelet drug 13（50％） 16（70％）
Antiarrhythmic drug 2（8％） 1（4％）
Anticoagulant 1（4％） 1（4％）
Antidiabetic drug 7（27％） 3（13％）
Lipid-lowering drug 4（15％） 5（22％）
Potassium binder 7（27％） 2（9％）
Phosphate binder 21（81％） 17（74％）
Vitamin D 11（42％） 10（43％）
Calcium mimetic 6（23％） 6（26％）
Drug for osteoporosis 4（15％） 1（4％）
Iron 5（19％） 3（13％）
erythropoiesis stimulating agent 20（77％） 18（78％）
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fistula thrombosis and cardiovascular diseases such as 
stroke and coronary artery disease. The doses of 
these drugs were not changed throughout the 12 
weeks of study. However, the dose of erythropoiesis 
stimulating agent（ESA）was modified so that the 
blood hemoglobin concentration was maintained 
between 10-12 g/dL according to the guideline of Jap-
anese Society of Dialysis Therapy 11）.
Figure 1 depicts the changes in pre-dialysis BP and 
heart rate during the 12 weeks of study in patients 
given allopurinol or febuxostat. Both systolic and dia-
stolic BPs were not significantly lowered in the allopu-
rinol group during the study period. In the febuxostat 
group, systolic BP was significantly reduced by 
5 mmHg at 4-week as compared with 0-week, while 
the systolic BPs at 8- and 12-week were not signifi-
cantly different from 0-week and the diastolic BP did 
not significantly changed during 12 weeks. The heart 
rate did not significantly alter either in the allopurinol 
or the febuxostat group throughout the study periods.
The changes in parameters of body fluid volume 
were depicted in Figure 2. Either the dry weight set-
ting or the cardiothoracic ratio on chest roentgeno-
gram did not significantly varied during the study, 
either in the allopurinol or the febuxostat groups. Nei-
ther did the body weight change between the dialysis 
sessions throughout the study in either group.
Table 3 shows the changes in hematological data 
and dose of ESA in the allopurinol and the febuxostat 
groups during the study period. These hematological 
parameters including blood hemoglobin and hemato-
crit did not significantly changed during the 12 weeks 
in either group. Darbepoetin alfa was the only ESA 
used in this study and the dose was significantly 
reduced at 8-week and 12-week as compared to 
0-week in the febuxostat group, while the dose was 
not changed in the allopurinol group（Figure 3）.
The changes in blood chemistry data during the 
study period were shown in Table 4. Serum proteins, 
liver enzymes and electrolytes such as Na, K and Ca 
were not significantly changed during 12 weeks in the 
allopurinol or the febuxostat group. Neither serum 
creatinine nor urea nitrogen significantly varied dur-
ing the study period. In contrast, serum uric acid was 
bpm
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????????
Time-course changes of blood pressure（BP）and heart rate during the 12-week study in chronic 
hemodialysis patients given allopurinol or febuxostat. ＊p＜0.05 versus 0-week.
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markedly reduced in the group given 20 mg febuxo-
stat, while the value was not significantly changed in 
the group given 100 mg allopurinol at 4-, 8- and 
12-week as compared with 0-week（Figure 4, left 
panel）. In addition, serum phosphate was significantly 
reduced in the febuxostat group at 8-week and 
12-week, while the value was not significantly 
changed in the allopurinol group during the study 
period（Figure 4, right panel）.
??????????
Hyperuricemia is generally recognized as a risk fac-
tor for cardiovascular diseases such as hypertension, 
stroke and coronary artery diseases 12〜16）and has also 
shown to be associated with the progression of renal 
dysfunction in patients with chronic kidney diseases
（CKD）12,17〜19）. Because the urinary excretion of uric 
acid is impaired in patients with decreased renal func-
tion, serum uric acid level is naturally increased in 
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????????
Time-course changes of dry weight, interdialysis weight gain and cardiothoracic ratio 
on chest roentgengram during the 12-week study in chronic hemodialysis patients 
given allopurinol or febuxostat.
???????　 Time-course changes in blood cell counts and erythropoietin dose during the study period in chronic hemodialysis 
patients given allopurinol or febuxostat
Allopurinol, n＝29 Febuxostat, n＝23
0-week 4-week 8-week 12-week 0-week 4-week 8-week 12-week
White blood cell, ×10 3/mm3 5.58±1.41 5.33±1.33 5.72±1.45 5.94±1.74 6.35±2.60 6.19±2.03 6.09±1.92 6.25±1.92
Red blood cells, ×10 6/mm3 349±50 349±46 358±46 349±44 358±60 358±54 361±49 354±50
Blood hemoglobin, g/dL 10.8±1.3 10.9±1.2 11.0±1.1 10.8±1.0 11.4±1.4 11.4±1.1 11.3±1.0 11.1±1.0
Hematocrit, ％ 33.2±4.0 33.5±3.7 34.4±3.5 33.4±3.1 34.9±4.7 34.9±3.9 34.6±3.3 33.7±3.2
Platelet, ×10 3/mm3 19.5±5.6 18.1±4.9 19.1±5.6 19.7±7.0 16.3±5.4 16.5±5.3 17.5±5.5 16.5±4.4
Dose of ESA, mg/wk 25.0±20.8 28.8±22.7 26.8±23.1 29.6±23.4 22.2±22.2 20.4±23.8 　16.7±17.5＊ 　17.1±18.5＊
Data are the mean±SD. ESA, erythropoiesis stimulating agent；darbepoetin alpha was used as ESA；＊p＜0.05 versus 
0-week.
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these patients. Therefore, hyperuricemia may be 
caused by reduced renal function and it seems 
unclear if hyperuricemia contributes to the pathogene-
sis of renal injuries 17,20）. However, it has been reported 
that the incidence of CKD was increased with increas-
ing serum uric acid level even in subjects with esti-
mated glomerular filtration rate（eGFR）higher than 
60 mL/min/1.73 m2 at baseline during the following 
10 years 21）. In addition, the pharmacological treatment 
of hyperuricemia with allopurinol has been shown to 
reduce the incidence of cardiovascular events and 
delay further deterioration of renal function in CKD 
patients 22 ,23）. Therefore, it is speculated that the 
increase in circulating levels of uric acid plays a role 
in the progression of renal and cardiovascular organ 
injuries.
As mentioned above, serum uric acid level is 
increased in large part of hemodialysis patients, how-
???????　 Time-course changes in blood chemistry data during the study period in chronic hemodialysis patients given 
allopurinol or febuxostat
Allopurinol, n＝29 Febuxostat, n＝23
0-week 4-week 8-week 12-week 0-week 4-week 8-week 12-week
Total protein, g/dL 6.5±0.4 6.3±0.4 6.5±0.5 6.5±0.4 6.3±0.5 6.3±0.5 6.5±0.3 6.6±0.4
Albumin, g/dL 3.6±0.4 3.9±0.5 3.9±0.3 3.9±0.6 3.5±0.4 3.6±0.3 3.7±0.3 3.8±0.2
AST, U/L 13±5 13±6 13±6 14±10 13±5 14±8 12±3 12±4
ALT, U/L 10±5 11±6 11±5 12±10 9±4 11±7 9±3 10±5
Urea nitrogen, mg/dL 64±19 66±16 67±15 71±20 68±12 67±12 64±13 62±15
Creatinine, mg/dL 11.2±3.3 11.0±2.8 11.3±2.5 11.1±2.7 10.2±2.8 10.0±2.8 10.0±2.9 10.1±2.9
Uric acid, mg/dL 6.0±1.0 6.1±1.0 5.8±1.1 5.8±1.5 6.7±0.9 　4.3±1.6† 　4.3±1.7† 　4.3±1.8†
Na, mEq/L 139±3 139±3 138±3 137±3 141±2 139±3 140±3 140±3
K, mEq/L 4.7±0.7 4.6±0.7 4.5±0.7 4.6±0.6 4.8±0.6 4.8±0.6 4.6±0.6 4.7±0.7
Ca, mg/dL 9.4±0.7 9.3±0.7 9.6±0.6 9.6±0.7 9.3±0.7 9.3±0.8 9.4±0.9 9.3±0.7
Phosphate, mg/dL 5.9±1.9 5.7±1.8 5.8±1.5 5.8±1.3 5.9±1.4 5.6±1.2 　　5.2±1.2＊＊ 　5.1±1.1＊
Data are the mean±SD. AST, aspartate aminotransferase；ALT, alanine aminotransferase. ＊p＜0.05, ＊＊p＜0.01, † p＜0.001 
versus 0-week.
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????????
Time-course changes of blood hemoglobin concentration and the dose of erythropoiesis 
stimulating agent（ESA）during the 12-week study in chronic hemodialysis patients given 
allopurinol or febuxostat. Darbepoetin alpha was used as ESA.
＊p＜0.05, ＊＊p＜0.01 versus 0-week.
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ever, it seems controversial whether the pharmacolog-
ical treatment for hyperuricemia benefits in terms of 
improving the prognosis of patients 24）. A J-shaped 
relationship has been observed between serum uric 
acid levels and mortality in the epidemiological studies 
of hemodialysis patients 25,26）. It has been suggested 
that the low serum uric acid level is caused by malnu-
trition which is associated with poor survival 27）. How-
ever, hyperuricemia has been assumed to promote the 
development and progression of atherosclerosis in 
hemodialysis patients 28） and acidosis caused by renal 
failure is supposed to facilitate precipitation and depo-
sition of uric acid in the cardiovascular tissue which 
certainly seems detrimental to the cardiovascular 
organs. Furthermore, it has been indicated that dialy-
sis patients experiencing gout, showed increased mor-
tality and high serum uric acid combined with low 
superoxide dismutase activity was associated with 
increased cardiovascular and all-cause mortality 29,30）. 
Therefore, the adequate control of serum uric acid 
seems desirable in order to reduce cardiovascular risk 
and mortality even in hemodialysis patients and avail-
ability of XOI excreted not only by the kidneys but 
also by the liver is appreciated to lower serum uric 
acid in renal failure patients.
It is assumed that atherosclerosis and arteriosclerot-
ic lesions are initiated by functional disorder of the 
vascular endothelium. This causes the reduced capaci-
ty to generate nitric oxide（NO）in response to vari-
ous stimuli resulting in impaired endothelium-depen-
dent vasorelaxation. The development of endothelial 
dysfunction is contributed by aging, smoking and life-
style-related diseases such as diabetes, hypertension 
and dyslipidemia. In addition to these classical risk 
factors of atherosclerosis, novel factors such as oxida-
tive stress and inflammation are thought to participate 
in the etiology and pathogenesis of endothelial dys-
function 31）. It is recognized that the endothelial dys-
function takes place from the early stage of CKD and 
is deeply involved in the development of cardiovascu-
lar disorders 32,33）. Thus, endothelial protection is rec-
ommended as a therapeutic target in the management 
of CKD patients 34）.
In order to attain maximum protection and preven-
tion against the development of arterial lesions, care 
should be considered not only to reduce classical risk 
factors but also to reduce vascular oxidative stress 
and vascular inflammation as well. In this context, 
although uric acid itself has antioxidative activity in 
nature, reactive oxygen species are generated as 
byproducts during the process of uric acid synthesis 
by xanthine oxidase 35〜39） and atihyperuricemic thera-
py with allopurinol has been shown to alleviate oxida-
tive stress and improve endothelial function in 
patients with CKD40〜42）. As described earlier, allopuri-
nol has been also shown to ameliorate the progression 
????????
Time-course changes of serum uric acid and phosphate during the 12-week study in chronic 
hemodialysis patients given allopurinol or febuxostat.
＊p＜0.05, ＊＊p＜0.01, †p＜0.001 versus 0-week.
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of renal impairment and reduced the incidence of car-
diovascular events in CKD patiets 22,23）. Febuxostat is 
a selective non-purine XOI characterized by higher 
bioavailability and more potent blockade of XO activi-
ty than allopurinol 6〜8,42）. Consequently, it has been 
indicated that febuxostat is more effective in lowering 
serum uric acid 6,43〜45）, which was confirmed by this 
study in hemodialysis patients. Febuxostat has been 
shown to be more potent in reducing the markers of 
oxidative stress and inflammation46,47）. Furthermore, 
the renoprotective effect of febuxostat is thought to 
be stronger than allopurinol considering that the 
increase in eGFR was observed after changing allopu-
rinol into febuxostat in patients with CKD43,48）.
As to the indices of arterial injuries, Tsuruta et al 
have demonstrated that the 4-week treatment with 
febuxostat improved the marker of oxidative stress 
and endothelial function in hemodialysis patients 49）. In 
addition, Tausche et al have observed superior effects 
on oxidative stress and pulse wave velocity by febux-
ostat as compared with allopurinol after the one-year 
treatment in patients including CKD50）. In the present 
study, systolic BP was significantly reduced at 
4-week period in the febuxostat group and it is specu-
lated that the effects of febuxostat on endothelial func-
tion and arterial stiffness may have participated, 
although the hypotensive effects were not observed at 
8-week and 12-week. The short-term treatment with 
allopurinol has been also reported to lower BP in 
young subjects by reducing peripheral vascular resis-
tance 51,52）. If these vascular effects of XOI were medi-
ated by inhibition of oxidative stress and inflamma-
tion, the effects are supposedly stronger in febuxostat 
than in allopurinol considering febuxostat has been 
shown to inhibit oxidative stress and inflammation 
more potently than allopurinol 46,47）.
In the present study, the dose of ESA was reduced 
at 8-week and 12-week in the febuxostat group, 
while blood hemoglobin was not significantly changed 
in either group. Because the ESA dose was modified, 
so that the blood hemoglobin was maintained between 
10-12 g/dL during the study, febuxostat may have 
improved the responsiveness to ESA in hemodialysis 
patients. It is known that oxidative stress and chronic 
inflammation are involved in the development of 
erythropoietin resistance in patients with renal ane-
mia 53〜55）. Therefore, it is speculated that more potent 
inhibitory effects of febuxostat on oxidative stress and 
inflammation than allopurinol may have contributed to 
the increase in responsiveness to ESA.
It seems hard to speculate plausible explanation on 
the mechanism by which febxostat reduced serum 
phosphate level in hemodialysis patients in this study. 
Considering that febuxostat has been shown to 
restore the hampered activation of vitamin D in 
hyperuricemic rat 56）, febuxostat may have decreased 
serum phosphate reciprocally to the increase in calci-
um. However, serum calcium levels were not signifi-
cantly changed in this study and further comprehen-
sive evaluation of mineral bone metabolism including 
PTH, active vitamin D and markers of osteogenesis 
and osteolysis to clarify the relationship between uric 
acid and phosphate.
In conclusion, this study demonstrated that 20 mg 
febuxostat is more effective in lowering serum uric 
acid than 100 mg allopurinol in chronic hemodialysis 
patients. Febuxostat also lowered BP temporally, 
improved responsiveness to ESA and reduced serum 
phosphate. These properties of febuxostat are expect-
ed to benefit in the long-term management of hemo-
dialysis patients in terms of preventing cardiovascular 
events and mortality.
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